Dr Reddy’s shares slide 7% after delay in semaglutide provides over high quality considerations
In an alternate submitting, the corporate stated sure batches of semaglutide have been discovered to be out of specification on account of a problem related to the API used within the product. It added that an investigation is underway to determine the basis trigger and that acceptable measures are being taken to make sure product high quality.
Dr Reddy’s stated industrial provides of the product shall be delayed till the difficulty is resolved. The corporate clarified that the event has no affect on affected person security or on the product’s present international regulatory filings. It additionally reiterated its dedication to making sure dependable international provides of the metabolic remedy.
Additionally learn: Margin revival, Semaglutide launch to drive Dr Reddy’s development momentum in FY27Dr Reddy’s additional stated its administration will host a convention name to debate the event and reply questions from members.
The disclosure comes lower than two months after Dr Reddy’s commercially launched its oral semaglutide pill underneath the model title Obeda in India for the therapy of type-2 diabetes. The once-daily oral drug is on the market in 3 mg, 7 mg and 14 mg strengths, priced at Rs 99, Rs 135 and Rs 225 per pill, respectively.
The corporate had positioned the launch as a key milestone in constructing its GLP-1 portfolio after additionally changing into one of many first corporations to launch a generic once-weekly injectable semaglutide in India following the expiry of the related patent earlier this 12 months.
Dr Reddy’s This fall snapshot
The pharma big reported 86% year-on-year (YoY) decline in consolidated internet revenue to Rs 221 crore for the January-March quarter of FY26, as towards Rs 1,587 crore within the year-ago interval, main to focus on worth cuts by brokerages.
Its income from operations, in the meantime, fell 12% YoY to Rs 7,516 crore through the quarter underneath evaluate, from Rs 8,506 crore reported within the corresponding quarter of the earlier monetary 12 months.
Learn extra: Dr Reddy’s launches generic Semaglutide injection, widespread weight-loss drug, in Canada
The decline in quarterly earnings was totally on account of decreased gross sales of Lenalidomide, worth erosion in North America and Europe Generics and a one-time SSA affect.
Dr Reddy’s share worth has remained flat in 2026, up 2% YTD. Within the final 5 years, the inventory has delivered a return of 17%.
(Disclaimer: Suggestions, ideas, views and opinions given by the specialists are their very own. These don’t characterize the views of The Financial Instances)
